These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Cetuximab may inhibit tumor growth and angiogenesis induced by ionizing radiation: a preclinical rationale for maintenance treatment after radiotherapy. Pueyo G; Mesia R; Figueras A; Lozano A; Baro M; Vazquez S; Capella G; Balart J Oncologist; 2010; 15(9):976-86. PubMed ID: 20798193 [TBL] [Abstract][Full Text] [Related]
3. C225 antiepidermal growth factor receptor antibody enhances tumor radiocurability. Nasu S; Ang KK; Fan Z; Milas L Int J Radiat Oncol Biol Phys; 2001 Oct; 51(2):474-7. PubMed ID: 11567823 [TBL] [Abstract][Full Text] [Related]
4. Infusion reactions to the chimeric EGFR inhibitor cetuximab--change to the fully human anti-EGFR monoclonal antibody panitumumab is safe. Resch G; Schaberl-Moser R; Kier P; Kopetzky G; Scheithauer W; Sliwa T; Greil R; Nösslinger T; Mayrbäurl B; Thaler J Ann Oncol; 2011 Feb; 22(2):486-7. PubMed ID: 21239398 [No Abstract] [Full Text] [Related]
5. Head and neck cancer as a clinical model for molecular targeting of therapy: combining EGFR blockade with radiation. Harari PM; Huang SM Int J Radiat Oncol Biol Phys; 2001 Feb; 49(2):427-33. PubMed ID: 11173137 [TBL] [Abstract][Full Text] [Related]
6. Anti-epidermal growth factor receptor antibodies in the treatment of metastatic colorectal cancer. Lee D Clin Colorectal Cancer; 2004 Sep; 4(3):159-62. PubMed ID: 15377399 [No Abstract] [Full Text] [Related]
9. Cellular and molecular properties of (90)Y-labeled cetuximab in combination with radiotherapy on human tumor cells in vitro. Saki M; Toulany M; Sihver W; Zenker M; Heldt JM; Mosch B; Pietzsch HJ; Baumann M; Steinbach J; Rodemann HP Strahlenther Onkol; 2012 Sep; 188(9):823-32. PubMed ID: 22875052 [TBL] [Abstract][Full Text] [Related]
10. Previously irradiated areas spared from skin toxicity induced by cetuximab in six patients: implications for the administration of EGFR inhibitors in previously irradiated patients. Bossi P; Liberatoscioli C; Bergamini C; Locati LD; Fava S; Rinaldi G; Orlandi E; Olmi P; Tagliabue E; Ménard S; Licitra L Ann Oncol; 2007 Mar; 18(3):601-2. PubMed ID: 17074970 [No Abstract] [Full Text] [Related]
11. Anti-epidermal growth factor receptor monoclonal antibody cetuximab augments radiation effects in glioblastoma multiforme in vitro and in vivo. Eller JL; Longo SL; Kyle MM; Bassano D; Hicklin DJ; Canute GW Neurosurgery; 2005; 56(1):155-62; discussion 162. PubMed ID: 15617598 [TBL] [Abstract][Full Text] [Related]
12. Cetuximab: its use in combination with radiation therapy and chemo-therapy in the multimodality treatment of head and neck cancer. Wagner TD; Yang GY Recent Pat Anticancer Drug Discov; 2008 Jun; 3(2):76-83. PubMed ID: 18537749 [TBL] [Abstract][Full Text] [Related]
13. Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab. Yonesaka K; Zejnullahu K; Okamoto I; Satoh T; Cappuzzo F; Souglakos J; Ercan D; Rogers A; Roncalli M; Takeda M; Fujisaka Y; Philips J; Shimizu T; Maenishi O; Cho Y; Sun J; Destro A; Taira K; Takeda K; Okabe T; Swanson J; Itoh H; Takada M; Lifshits E; Okuno K; Engelman JA; Shivdasani RA; Nishio K; Fukuoka M; Varella-Garcia M; Nakagawa K; Jänne PA Sci Transl Med; 2011 Sep; 3(99):99ra86. PubMed ID: 21900593 [TBL] [Abstract][Full Text] [Related]
14. The effects of cetuximab alone and in combination with radiation and/or chemotherapy in lung cancer. Raben D; Helfrich B; Chan DC; Ciardiello F; Zhao L; Franklin W; Barón AE; Zeng C; Johnson TK; Bunn PA Clin Cancer Res; 2005 Jan; 11(2 Pt 1):795-805. PubMed ID: 15701870 [TBL] [Abstract][Full Text] [Related]
15. 18F-fluorothymidine PET/CT as an early predictor of tumor response to treatment with cetuximab in human lung cancer xenografts. Takeuchi S; Zhao S; Kuge Y; Zhao Y; Nishijima K; Hatano T; Shimizu Y; Kinoshita I; Tamaki N; Dosaka-Akita H Oncol Rep; 2011 Sep; 26(3):725-30. PubMed ID: 21667030 [TBL] [Abstract][Full Text] [Related]
16. Cetuximab in cancers of the lung and head & neck. Kim ES; Vokes EE; Kies MS Semin Oncol; 2004 Feb; 31(1 Suppl 1):61-7. PubMed ID: 14981582 [TBL] [Abstract][Full Text] [Related]
17. Phase II study evaluating the addition of cetuximab to the concurrent delivery of weekly carboplatin, paclitaxel, and daily radiotherapy for patients with locally advanced squamous cell carcinomas of the head and neck. Suntharalingam M; Kwok Y; Goloubeva O; Parekh A; Taylor R; Wolf J; Zimrin A; Strome S; Ord R; Cullen KJ Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):1845-50. PubMed ID: 21601372 [TBL] [Abstract][Full Text] [Related]
18. Long term responses with cetuximab therapy in glioblastoma multiforme. Lustig R Cancer Biol Ther; 2006 Sep; 5(9):1242-3. PubMed ID: 17035733 [No Abstract] [Full Text] [Related]
19. Radiosensitisation of U87MG brain tumours by anti-epidermal growth factor receptor monoclonal antibodies. Diaz Miqueli A; Rolff J; Lemm M; Fichtner I; Perez R; Montero E Br J Cancer; 2009 Mar; 100(6):950-8. PubMed ID: 19293809 [TBL] [Abstract][Full Text] [Related]
20. Preclinical modeling of EGFR inhibitor resistance in head and neck cancer. Quesnelle KM; Wheeler SE; Ratay MK; Grandis JR Cancer Biol Ther; 2012 Aug; 13(10):935-45. PubMed ID: 22785204 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]